for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ACADIA Pharmaceuticals Inc.

ACAD.OQ

Latest Trade

39.90USD

Change

-0.26(-0.65%)

Volume

455,673

Today's Range

39.62

 - 

40.47

52 Week Range

14.01

 - 

44.84

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Acadia Pharmaceuticals Prices Underwritten Public Offering Of 6.25 Mln Shares At $40/Shr

Sept 17 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.ACADIA PHARMACEUTICALS - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 6.25 MILLION SHARES OF COMMON STOCK AT PRICE TO PUBLIC OF $40.00 PER SHARE.

Acadia Pharmaceuticals - Intends To Offer And Sell $250 Million Of Its Common Stock

ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ACADIA PHARMACEUTICALS - INTENDS TO OFFER AND SELL $250 MILLION OF ITS COMMON STOCK.

Acadia Pharmaceuticals Announces Pivotal Phase 3 Harmony Trial Stopped Early For Positive Efficacy As Pimavanserin Meets The Primary Endpoint In Patients With Dementia-Related Psychosis

Sept 9 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS ANNOUNCES PIVOTAL PHASE 3 HARMONY TRIAL STOPPED EARLY FOR POSITIVE EFFICACY AS PIMAVANSERIN MEETS THE PRIMARY ENDPOINT IN PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS.ACADIA PHARMACEUTICALS INC - PHASE 3 HARMONY STUDY MET ITS PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - PIMAVANSERIN ACHIEVED ROBUST STATISTICAL SUPERIORITY OVER PLACEBO IN STUDY.ACADIA PHARMA - STUDY TO BE STOPPED EARLY BASED ON PRE-SPECIFIED STOPPING CRITERIA REQUIRING ONE-SIDED P-VALUE LESS THAN 0.0033 ON STUDY'S PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - COMPANY IS PLANNING TO MEET WITH FDA REGARDING A SUPPLEMENTAL NDA SUBMISSION IN 2020.

Acadia Pharma Reports Second Quarter Loss Per Share Of $0.38

July 31 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.38.Q2 SALES $83.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $72.6 MILLION.SEES FY 2019 SALES $320 MILLION TO $330 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.45 -- REFINITIV IBES DATA.ACADIA PHARMACEUTICALS - AT JUNE 30, 2019, ACADIA'S CASH, CASH EQUIVALENTS, AND INVESTMENT SECURITIES TOTALED $381.9 MILLION.2019 GAAP SG&A GUIDANCE IS INCREASED TO $300 MILLION TO $315 MILLION.

Acadia Pharma Says Pimavanserin Did Not Achieve Statistical Significance On Primary Endpoint

July 22 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM PHASE 3 ENHANCE TRIAL OF PIMAVANSERIN AS ADJUNCTIVE TREATMENT FOR PATIENTS WITH SCHIZOPHRENIA.ACADIA PHARMACEUTICALS INC - PIMAVANSERIN DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - IN STUDY, SIGNIFICANT IMPROVEMENTS OBSERVED ON SECONDARY ENDPOINT OF PANSS NEGATIVE SYMPTOMS SCALE SUB-SCORE.

Acadia Pharmaceuticals Q1 Loss Per Share $0.59

May 1 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.59.Q1 SALES $63 MILLION VERSUS REFINITIV IBES ESTIMATE OF $60.7 MILLION.SEES FY 2019 SALES $280 MILLION TO $300 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.52 -- REFINITIV IBES DATA.ACADIA PHARMACEUTICALS - AT MARCH 31, 2019, CASH, CASH EQUIVALENTS, & INVESTMENT SECURITIES TOTALED $414.3 MILLION, COMPARED TO $473.5 MILLION AT DEC 31, 2018.FY2019 REVENUE VIEW $291.2 MILLION -- REFINITIV IBES DATA.

Acadia Pharmaceuticals Says Co Submitted Update To Data Available Through Centers For Medicare And Medicaid Services Open Payments Database

March 6 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS - ON MARCH 5, CO SUBMITTED UPDATE TO DATA AVAILABLE THROUGH CENTERS FOR MEDICARE AND MEDICAID SERVICES OPEN PAYMENTS DATABASE.ACADIA PHARMACEUTICALS - UPDATE IS TO RECLASSIFY CERTAIN CATEGORIZATION INFORMATION REGARDING GENERAL PAYMENTS PROVIDED TO PHYSICIANS.ACADIA PHARMACEUTICALS SAYS UPDATE WILL BE REFLECTED IN PUBLICLY AVAILABLE DATA POSTED ON OPENPAYMENTSDATA.CMS.GOV ON JUNE 30 - SEC FILING.

Acadia Pharmaceuticals Reports Fourth Quarter Results

Feb 26 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 SALES $59.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $59.5 MILLION.Q4 LOSS PER SHARE $0.50.Q4 EARNINGS PER SHARE ESTIMATE $-0.55 -- REFINITIV IBES DATA.SEES 2019 NET SALES OF $275 MILLION TO $300 MILLION.ACADIA PHARMACEUTICALS - PLANS TO INITIATE TWO PHASE 3 TRIALS FOR PIMAVANSERIN AS ADJUNCTIVE TREATMENT FOR MDD IN FIRST HALF OF 2019.ACADIA PHARMACEUTICALS - AT DEC 31, 2018, CASH, CASH EQUIVALENTS, & INVESTMENT SECURITIES TOTALED $473.5 MILLION, COMPARED TO $341.3 MILLION AT DEC 31, 2017.NUPLAZID NET SALES ARE EXPECTED TO BE BETWEEN $275 MILLION AND $300 MILLION IN 2019.

Acadia Pharmaceuticals Prices Public Offering Of Common Stock

Nov 28 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 16.2 MILLION COMMON SHARES PRICED AT $17.00PER SHARE.GROSS PROCEEDS FROM OFFERING TO CO EXPECTED TO BE ABOUT $275.0 MILLION.OFFERING IS EXPECTED TO CLOSE ON NOVEMBER 30, 2018.

Acadia Pharmaceuticals Files For Potential Stock Shelf Offering

Nov 26 (Reuters) - ACADIA Pharmaceuticals Inc <ACAD.O>::ACADIA PHARMACEUTICALS INC FILES FOR POTENTIAL STOCK SHELF OFFERING; SIZE NOT DISCLOSED .

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up